Research programme: optogenetic therapy- Applied Genetic Technologies Corporation/Bionic Sight

Drug Profile

Research programme: optogenetic therapy- Applied Genetic Technologies Corporation/Bionic Sight

Alternative Names: AAV-based optogenetic therapies

Latest Information Update: 11 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Applied Genetic Technologies Corporation; Bionic Sight
  • Developer Applied Genetic Technologies Corporation
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Blindness

Most Recent Events

  • 07 Nov 2017 AGTC in collaboration with Bionic Sight plans to file an IND application with the US FDA in USA for Blindness in 2018
  • 24 Jan 2017 Applied Genetic Technologies Corporation and Bionic Sight agree to co-develop optogenetic therapy for Blindness
  • 24 Jan 2017 Preclinical trials in Blindness in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top